Treatment of BPH with transurethral electrovaporization of the prostate (TUVP) using vaportrode VE-B. Two years follow-up.
The Authors report their experience on trasurethral vaporization of the prostate with Vaportrode for the treatment of BPH. In January 1996 we treated 24 patients suffering from cervico-urethral obstruction caused by BPH with electrovaporization of the prostate using a cutting current of between 180 and 250 Watts (average 200 Watts). Exclusion criteria was: PSA > 3 ng/ml. The catheter was removed after 24 hours. Follow-up of all patients is 27 months. 23 patients were evaluated. Results at follow-up were: mean maximum flow (Qmax) 9.31 ml/sec preoperative was 19.5 ml/sec after 6 months, 18.3 after 12 months and 18.0 after 24 months; mean symptom score decreased from 18.1 to 10.4 after 6 months, to 3.2 after 12 months and to 4.8 after 24 months; QL index decreased from 4.6 to 2.3 at 6 months, to 1.4 after 12 months and 24 months; the average voiding pressure decreased from 62.8 cm/H20 to 23.2 cm/H20 after 6 months, to 21.2 after 12 months and to 23.8 after 24 months. There was no post voiding residual urine 2 days after treatment in all patients. Follow-up shows transurethral electrovaporization of the prostate is an efficient and safe technique for treatment of BPH.
Diana
M
M
Divisione di Urologia, Ospedale Generale di zona Cristo Re, Roma, Italia.
Schettini
M
M
Gallucci
M
M
D000368:Aged; D004566:Electrodes; D004598:Electrosurgery / Q000295:instrumentation; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000601:surgery*; D014524:Urethral Obstruction / Q000209:etiology